ActHIB vaccine recalled in Japan

Mar 11, 2011

Sanofi Pasteur and Daiichi Sankyo on Friday announced a recall of the ActHIB vaccine in Japan after an "unidentified substance" was found in two syringes.

Daiichi is the Japan marketer of the vaccine manufactured by Sanofi Pasteur, a wing of Paris-headquartered Sanofi-Aventis. The drug is used to prevent bacterial infections causing pneumonia and meningitis.

However, Daiichi told AFP most of the 1.3 million dose shipment had already been used and only a small percentage remained.

A Sanofi Pasteur official told AFP the company was checking how many vaccines had been used.

The official in Tokyo said that the doses "were manufactured on a production line dedicated to the Japanese market".

"They were delivered between September 2010 and late January 2011 but were produced about six months earlier," he added.

Japan's health ministry last week suspended the vaccine along with Pfizer's Prevenar, also used against that can cause and .

The ministry is investigating the recent deaths of six infants who were administered either one or both of the treatments, or in combination with other drugs.

Both Pfizer and Sanofi-Aventis have vouched for the safety of their vaccines and said they are cooperating with the investigation in .

Explore further: Anti-cholinergic drugs impair physical function in elderly patients

add to favorites email to friend print save as pdf

Related Stories

Japan reports sixth infant death after vaccination

Mar 10, 2011

Japan's health ministry on Thursday reported the death of a sixth infant who recently received vaccinations made by Pfizer or Sanofi-Aventis that have been suspended since last week. ...

Kids' Swine flu shots recalled; not strong enough

Dec 15, 2009

(AP) -- Hundreds of thousands of swine flu shots for children have been recalled because tests indicate the vaccine doses lost some strength, government health officials said Tuesday.

Sanofi to deliver swine flu vaccine in October

Sep 21, 2009

(AP) -- Sanofi-Aventis SA will begin delivering the first doses of its new swine flu vaccine in the United States by mid-October, the head of France's largest pharmaceutical company said Monday.

Recommended for you

FDA to start regulating lab-developed tests

19 hours ago

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments : 0